These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 10809342)
1. Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function. Neuhauser MM; McKinnon PS; Hershberger E; Rybak MJ Pharmacotherapy; 2000 May; 20(5):554-61. PubMed ID: 10809342 [TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime. Sánchez-Navarro A; Colino CI; Sánchez Recio MM Clin Pharmacokinet; 2001; 40(2):125-34. PubMed ID: 11286322 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Tam VH; McKinnon PS; Akins RL; Drusano GL; Rybak MJ Antimicrob Agents Chemother; 2003 Jun; 47(6):1853-61. PubMed ID: 12760858 [TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients. Facca B; Frame B; Triesenberg S Antimicrob Agents Chemother; 1998 Jul; 42(7):1783-7. PubMed ID: 9661021 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties. Kays MB; White RL; Friedrich LV; Del Bene VE Clin Ther; 1991; 13(5):596-605. PubMed ID: 1799917 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. McKinnon PS; Paladino JA; Schentag JJ Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ceftizoxime in renal failure patients without dialysis. Li P; Cai Q; Gao S; Liu GL; Cui RL; Yang XY Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):402-4. PubMed ID: 8701753 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cefodizime in patients with various degrees of renal failure. Loffreda A; Lampa E; Lucarelli C; Amorena M; Contaldi C; Calderaro V; Rossi F Chemotherapy; 1999; 45(1):1-7. PubMed ID: 9876203 [TBL] [Abstract][Full Text] [Related]
11. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Aitken SL; Altshuler J; Guervil DJ; Hirsch EB; Ostrosky-Zeichner LL; Ericsson CD; Tam VH Int J Antimicrob Agents; 2015 May; 45(5):541-4. PubMed ID: 25665726 [TBL] [Abstract][Full Text] [Related]
12. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Lipman J; Wallis SC; Rickard CM; Fraenkel D Intensive Care Med; 2001 Feb; 27(2):363-70. PubMed ID: 11396280 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of sparfloxacin in patients with renal impairment. Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518 [TBL] [Abstract][Full Text] [Related]
14. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Stangier J; Rathgen K; Stähle H; Mazur D Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409 [TBL] [Abstract][Full Text] [Related]
15. Simulation of human plasma levels of beta-lactams in mice by multiple dosing and the relationship between the therapeutic efficacy and pharmacodynamic parameters. Hatano K; Wakai Y; Watanabe Y; Mine Y Chemotherapy; 1994; 40(1):1-7. PubMed ID: 8306809 [TBL] [Abstract][Full Text] [Related]
16. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. O'Grady P; Yee KF; Lins R; Mangold B Br J Clin Pharmacol; 1999 Sep; 48(3):375-81. PubMed ID: 10510149 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975 [TBL] [Abstract][Full Text] [Related]
18. [A clinical assessment on intramyocardial transfer of ceftizoxime (CZX)]. Sezai Y; Hasegawa T; Kitamura S; Rikukawa H; Shindo S; Shiono M; Orime Y; Niino S Rinsho Kyobu Geka; 1988 Dec; 8(6):582-6. PubMed ID: 9301887 [No Abstract] [Full Text] [Related]
19. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients. Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396 [TBL] [Abstract][Full Text] [Related]
20. Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment. Katsube T; Echols R; Arjona Ferreira JC; Krenz HK; Berg JK; Galloway C J Clin Pharmacol; 2017 May; 57(5):584-591. PubMed ID: 27874971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]